oncology breakthroughs

In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…

The alpha-synuclein, a protein long associated with Parkinson’s disease may hold the key to melanoma proliferation. The study, published in Science Advances, on 9 April, suggests that while excess alpha-synuclein results in cell death in neurons, conversely, it enables uncontrolled…